Search Results

You are looking at 81 - 90 of 461 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

scientific peer-review process and are overseen by the ORP. NCCN-sponsored studies funded through the grant mechanism are highlighted below. A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck

Full access

Benjamin E. Greer, Ron E. Swensen, and Heidi J. Gray

carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: A Gynecolog Oncology Group study (Abstr 1) . Gynecol Oncol 2003 ; 88 : 156 . 9 Ayhan A Tuncer ZS Tuncer R . Is routine appendectomy beneficial in the

Full access

Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner

disease may also undergo intraperitoneal chemotherapy, although no randomized evidence for stage II disease has been published. 61 , 63 , 64 In women with stage III cancer, survival was increased by 16 months after intraperitoneal therapy using cisplatin/paclitaxel

Full access

William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab, and pertuzumab until disease progression or unacceptable toxicity. The preliminary results after 52 months median follow-up show that median PFS was comparable between

Full access

David M. O’Malley

ICON7. 1 , 2 A 3-arm trial that enrolled 1,873 patients with newly diagnosed stage III–IV ovarian cancer, GOG-0218 randomly assigned patients 1:1 to carboplatin/paclitaxel followed by placebo maintenance therapy; carboplatin/paclitaxel

Full access

Yi-Jen Chen

) for Anal Carcinoma recommend using 5-FU/cisplatin, carboplatin/paclitaxel, or FOLFOX (5-FU/leucovorin/oxaliplatin) as first-line treatment for MAC. 2 The recently reported randomized, international, multicenter, phase II InterAACT study found that

Full access

Presenters: Crystal S. Denlinger, Kristina A. Matkowskyj, and Mary F. Mulcahy

treatment options now exist that come on the heels of several negative phase II studies: the TyTAN trial of paclitaxel + lapatinib, 6 the GATSBY trial of trastuzumab emtansine (T-DM1) versus a taxane, 7 and the T-ACT trial of paclitaxel + trastuzumab. 8

Full access

Tanya E. Keenan and Sara M. Tolaney

atezolizumab and nab-paclitaxel (NCT01375842) showed a promising ORR of 39.4% in 33 patients, also treated with 0 to 2 prior lines, 27 perhaps related to the ability of taxanes to promote toll-like receptor activity and dendritic cell activation. 28 The

Full access

David Scott Miller, Gini Fleming, and Marcus E. Randall

paclitaxel: a Gynecologic Oncology Group study . Gynecol Oncol 2009 ; 112 : 543 – 552 . 13 Fleming GF Brunetto VL Cella D . Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial

Full access

Robert J. Morgan Jr

improvement in OS with less toxicity, because by the time it was published paclitaxel had already been proven to be a superior second agent, and the oncology community felt that intraperitoneal chemotherapy was not necessary in the age of the taxanes. Annual